Clinical Trials

Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.

 

Sarcoma Trials

 

  • STUDY8700

    Molecular Analysis for Therapy Choice (MATCH)

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.

    Study Information



  • STUDY17022

    First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Study Information



  • STUDY21565

    A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor



    Study Information



  • STUDY21654

    Feasibility Trial of Preoperative 5 Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma

    To determine the feasibility of preoperative 5-day HFRT for extremity STS within the HCC patient population Secondary Objectives: To evaluate the rates of favorable pathologic response, major woundcomplications, local control, acute toxicity, and 1-year late toxicity associated with preoperative 5-day HFRT Exploratory Objectives: To compare the socio-demographic profile of trial participants with those of extremity STS patients who would have meet trial criteria and were offered preoperative CFRT in the 3 years prior to the study opening at HCC To compare the retention rate for radiotherapy at HCC in patients meeting trial criteria during the prior 3 years with the retention rate for radiotherapy during the study period To compare serum levels of SFRP2 before and after preoperative 5-day HFRT To evaluate changes in serum SFRP2 levels before and after preoperative 5-day HFRT for an association with favorable pathologic response To evaluate patient satisfaction with the decision to participate in a trial of preoperative 5-day HFRT To assess the importance of the shorter duration of radiotherapy in an individual patient?s decision to participate in the study

    Study Information